2020
DOI: 10.1128/jvi.00647-20
|View full text |Cite
|
Sign up to set email alerts
|

The Nucleocapsid Protein of SARS–CoV-2: a Target for Vaccine Development

Abstract: KEYWORDS coronavirus disease 2019 (COVID-19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), nucleocapsid protein, vaccine D uring the current coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there has been an unprecedented level of global collaboration that has led to a rapid characterization of SARS-CoV-2 (1). Its sequence shares 79.6% identity to SARS-CoV (1, 2), the infectious virus that caused an epidemic in 2003 (2, 3). SA… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

3
321
1

Year Published

2020
2020
2022
2022

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 359 publications
(330 citation statements)
references
References 24 publications
3
321
1
Order By: Relevance
“…11 The N protein, on the other hand, has been described to be highly immunogenic and expressed in large quantities during acute infection of SARS-CoV-2. 12 Western blot studies also indicate that the N protein is a potent viral antigen for SARS-CoV-2 on the basis of IgG, IgA and IgM antibodies directed against N protein in COVID-19 positive sera. 13 To our knowledge, our study is the first which investigated and compared immunoassays with different design configurations against the S1 subunit, RBD protein, and N antigen, including that of a surrogate viral neutralising antibody (NAb) assay.…”
Section: Discussionmentioning
confidence: 92%
“…11 The N protein, on the other hand, has been described to be highly immunogenic and expressed in large quantities during acute infection of SARS-CoV-2. 12 Western blot studies also indicate that the N protein is a potent viral antigen for SARS-CoV-2 on the basis of IgG, IgA and IgM antibodies directed against N protein in COVID-19 positive sera. 13 To our knowledge, our study is the first which investigated and compared immunoassays with different design configurations against the S1 subunit, RBD protein, and N antigen, including that of a surrogate viral neutralising antibody (NAb) assay.…”
Section: Discussionmentioning
confidence: 92%
“…Together, the ORF8 BioID interactome did not provide striking clues to narrow down its putative functions in cells. expressed during infection 155,156 . N binds viral RNA through both its Nand C-terminal domains, connected by a disordered SR-rich linkage region 157,158 .…”
Section: Nsp14 Associates With Rna Decapping and Deadenylation Host Fmentioning
confidence: 99%
“…However, several labs reported cases in which the N gene was the only gene detected at high Ct (>36) which was, instead, undetectable by re-testing some subjects the day after (unpublished observations). Although conserved among coronaviruses, it has been shown that the N gene exhibited a great variability ( Wang et al, 2020 ; Ceraolo and Giorgi, 2020 ; Dutta et al, 2020 ). Besides the variability of replicate specimens and of the run’s volume reactions, it can be hypothesized that the uncertainty on N positive results could be linked to a transient stage of virus-host contact and its transitory detection to its high abundancy.…”
Section: Discussionmentioning
confidence: 99%